10 results
The aim of this study is to investigate the immune response to a tetravalent MenACWY-TT vaccine in 10-, 12- and 15-year old children primed with the monovalent MenC-TT conjugate vaccine at a young age and to1. determine whether the MenC-specific…
Primary Objectives: - To compare the pCR rate of neoadjuvant nivolumab/BMS-986205 + GC to neoadjuvant GC alone in all randomized participants. - To compare EFS of neoadjuvant nivolumab/BMS-986205 +GC followed by continued nivolumab/BMS-986205 after…
The study objectives and endpoints described below will be evaluated for the following treatment regimens:• Arm A: Nivolumab + CCRT followed by nivolumab + ipilimumab maintenance• Arm B: Nivolumab + CCRT followed by nivolumab maintenance• Arm C:…
The purpose of Part 1A is to investigate how safe RO7112689 is and how well RO7112689 is tolerated. Part 1A will also investigate how quickly and to what extent RO7112689 is absorbed into, distributed in, and eliminated from the body (this is called…
The study will look at patients with advanced Non-Small Cell Lung Cancer (NSCLC) whose tumours express a certain type of protein called PD-L1. The research aims to compare a new drug called nivolumab against Investigator's choice of…
The study will look at patients with chemotherapy-naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC). The research aims to compare a new drug called nivolumab OR nivolumab with ipilimumab (another cancer drug) OR nivolumab combined with…
The main objective of this study is to determine differences in vaccine responses in the pre-elderly age group (50-65 years of age) to a primary immunization with vaccine antigens to which no or (very) low pre-vaccination antibody levels and memory…
Primary Objective• To compare the event-free survival (EFS) by blinded independent central review (BICR) in Arm A (vs Arm B participantsSecondary Objectives• To compare the overall survival (OS) in Arm A vs Arm B participants• To assess the…
The aim of this study is to investigate the immune response to a primary and a booster immunization with a tetravalent MenACWY-TT conjugate vaccine in older persons aged 65-85 years of age.
The study aims to demonstrate that treatment with nivolumab combined with ipilimumab will improve efficacy in cisplatin-ineligible participants with previously untreated unresectable or metastatic UC and also treatment with nivolumab combined with…